EGFR and glioblastoma: A possible solution to antigen loss in GBM was tested in studies of EGFRvIII-directed CAR-NK cell therapy, where it was found to be prevented by treatment with CAR-NK transduced with bispecific CAR constructs targeting both mutated and wild-type EGFR.